Purpose

The primary objective of this study is to determine whether treatment with pimavanserin or quetiapine is associated with a greater improvement in psychosis when used in a routine clinical setting to treat hallucinations and/or delusions due to Parkinson's disease (PD) or dementia with Lewy bodies (DLB) - collectively referred to as Lewy body disease (LBD).

Category

IRB Number
20220198HU
NCT Number
NCT05590637
Sponsor
The University of Texas Health Science Center at San Antonio -



Study Contact

Carolyn Paiz
210-450-8830
paizc@uthscsa.edu

Principal Investigator
Sarah Horn

Victoria Carranza
210-450-8907
carranzav@uthscsa.edu

Omalys Biggs Rodriguez
210-450-8456
biggsrodrigu@uthscsa.edu

Carolyn Paiz
210-450-8830
paizc@uthscsa.edu

Charlotte Rhodes
210-450-8454
rhodesc1@uthscsa.edu



Eligibility

Eligible Ages
18+
Eligible Genders
male and female
Accepts Healthy Volunteers
No

Inclusion Criteria

    diagnosed with hallucinations due to Parkinson's disease or dementia with Lewy bodies

Exclusion Criteria

    currently taking an antipsychotic medication


Study Design

pragmatic clinical trial

Arm Groups

quetiapine versus pimavanserin